Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results août 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets août 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit juillet 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results mai 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 mai 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May avril 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 avril 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event mars 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing mars 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences mars 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 février 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform décembre 22, 2022 at 11:15 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 novembre 14, 2022 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2022 Operating and Financial Results novembre 09, 2022 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference novembre 03, 2022 at 11:00 AM UTC
Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs août 11, 2022 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2022 Operating and Financial Results août 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium juin 28, 2022 at 11:00 AM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates juin 01, 2022 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022 mai 09, 2022 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2022 Operating and Financial Results mai 05, 2022 at 08:30 PM UTC
Internal link ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 avril 26, 2022 at 08:10 PM UTC
Internal link ProQR to Participate in the Kempen Life Sciences Conference avril 19, 2022 at 08:30 PM UTC
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy avril 13, 2022 at 11:00 AM UTC